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Abstract
Possession of a properly functioning innate immune system in the lung is vital to prevent infections due to the ongoing
exposure of the lung to pathogens. While mechanisms of pulmonary innate immunity have been well studied, our
knowledge of how these systems are altered in disease states, leading to increased susceptibility to infections, is limited.
One innate immune protein in the lung, the pulmonary collectin SP-D, has been shown to be important in innate immune
defense, as well as clearance of allergens and apoptotic cells. MMP-9 is a protease with a wide variety of substrates, and has
been found to be dysregulated in a myriad of lung diseases ranging from asthma to cystic fibrosis; in many of these
conditions, there are decreased levels of SP-D. Our results indicate that MMP-9 is able to cleave SP-D in vitro and this
cleavage leads to loss of its innate immune functions, including its abilities to aggregate bacteria and increase phagocytosis
by mouse alveolar macrophages. However, MMP-9-cleaved SP-D was still detected in a solid-phase E. coli LPS-binding assay,
while NE-cleaved SP-D was not. In addition, MMP-9 seems to cleave SP-D much more efficiently than NE at physiological
levels of calcium. Previous studies have shown that in several diseases, including cystic fibrosis and asthma, patients have
increased expression of MMP-9 in the lungs as well as decreased levels of intact SP-D. As patients suffering from many of the
diseases in which MMP-9 is over-expressed can be more susceptible to pulmonary infections, it is possible that MMP-9
cleavage of SP-D may contribute to this phenotype.
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Introduction
Of the more than twenty matrix metalloproteases, matrix
metalloprotease 9 (MMP-9) is one of the most well studied, both in
vitro and in vivo, within the context of normal and several disease
states. Also known as 92-kDa gelatinase, or gelatinase B, MMP-9
has a variety of substrates and roles in functions as diverse as tissue
remodeling, tissue repair, and regulation of inflammation [1].
More than 30 substrates have been discovered for MMP-9,
including gelatin, type IV and V collagens, TNF-a, a variety of
surface receptors [including vascular endothelial growth factor
receptor-2, beta2-adrenergic receptor, and ICAM-1 (reviewed in
[2]], protease nexin-1, interleukin (IL) 8, IL-1b, and leukemia
inhibitory factor [3,4,5,6,7]. MMP-9 has a structure similar to
other matrix metalloproteases, and includes four domains: an N-
terminal signal sequence, a pro-domain region, an active catalytic
domain, and a hemopexin-like C-terminal domain (reviewed in
[8]). The prodomain region must be cleaved in order for the
protein to become active.
Due to its many functions in the body, MMP-9 dysregulation
has been implicated in a variety of diseases. MMP-9 expression
and activation levels have been shown to be elevated in lower
airway secretions and/or serum of smokers and patients with
chronic obstructive pulmonary disorder (COPD), emphysema,
idiopathic pulmonary fibrosis (IPF), acute respiratory distress
syndrome (ARDS), cystic fibrosis (CF), and asthma after allergen
challenge [9,10,11,12,13,14,15,16,17,18,19]. Whilst the role that
MMP-9 plays in these conditions is not fully understood, emerging
evidence from in vitro studies and animal models suggests that
MMP-9 may be contributing to the pathogenesis of these disorders
rather than being a response to them (reviewed in [1]). An increase
in cleavage of various MMP-9 substrates can result in an increase
in inflammation in vitro, and inflammation in vivo results in
alterations in clinical outcomes in patients with many of these
pulmonary conditions.
MMP-9 expression is also altered during infections by several
different pathogens. MMP-9 is increased in bronchoalveolar
lavage fluid during hospital-associated pneumonia and Pseudomonas
aeruginosa infections, in serum during Mycobacterium tuberculosis and
Helicobacter pylori infections, and in cerebrospinal fluid during
Klebsiella pneumonia meningitis [20,21,22,23]. Although MMP-9-
deficient mice are more susceptible to systemic Streptococcal
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infections and Escherchia coli peritonitis, the knockouts are less
susceptible to pulmonary Francisella tularensis and urogenital
Chlamydia muridarum infections [24,25,26,27]. It is, therefore, likely
that MMP-9 has a variety of functions in host immune defense.
Interestingly, patients with many of the lung diseases in which
MMP-9 levels are elevated are also more susceptible to pulmonary
infections, such as in COPD and CF.
One molecule in the lung that also has roles in regulation of
inflammation and the innate immune defense is Surfactant Protein
D (SP-D) (reviewed in [28,29]). In addition to these roles, SP-D is
also involved in surfactant homeostasis. It belongs to the collectin
family of pathogen recognition receptors, and its structure consists
of two main regions: a collagen-like domain and a carbohydrate
recognition (or lectin) domain (CRD). It is able to bind to a variety
of pathogens through this CRD. In vivo, SP-D is found in
homotrimers which are associated through their collagen-like
domains, and four homotrimers can further associate to form
a cruciform-like dodecamer. It is through this multimerization that
SP-D is able to cause the formation of aggregates of pathogens and
allergens (reviewed in [30]).
Similar to MMP-9, SP-D is thought to be involved in the
mechanism behind the pathology of many pulmonary diseases,
including asthma, smoking-associated respiratory problems,
COPD, IPF, and cystic fibrosis. The concentration of SP-D is
increased in the serum of COPD, IPF, and CF patients, increased
in the lungs of asthmatics after allergen challenge, and decreased
in the lungs of smokers [31,32,33,34,35,36]. Its roles in these
diseases are likely due to its functions in surfactant homeostasis as
well as regulation of inflammation. SP-D has also been found to be
important in the pulmonary defense against many pathogens, and
is able to directly interact with viruses, fungi, and bacteria
(reviewed in [30]). SP-D knockout mice have been shown to be
more susceptible to respiratory infections with Streptococcus
pneumoniae, Pseudomonas aeruginosa, Pneumocystis carinii, Influenza A
virus, Respiratory syncytial virus, and Aspergillus fumigatus
[37,38,39,40,41,42].
Due to the overlap of alterations in MMP-9 and SP-D in
pulmonary diseases and infections, we sought to examine the
effects that MMP-9 has upon SP-D in vitro. We hypothesized that
SP-D may serve as a substrate for MMP-9 as SP-D contains
a collagen-like region and MMP-9 has the ability to cleave
collagen. Experiments were performed to examine interactions
between purified recombinant proteins, and several in vitro assays
demonstrate the ability of MMP-9 to abrogate the innate immune
functions of SP-D.
Results
MMP-9 Cleaves SP-D
To determine if SP-D could be cleaved by MMP-9, recombi-
nant MMP-9 and recombinant SP-D were incubated together at
37uC. Intact recombinant SP-D monomers were detected as
a ,43 kDa band using SDS-PAGE under reducing conditions
(with minor ,27 and ,23 kDa bands). Incubation with MMP-9
led to the formation of two prominent bands at,23 and,17 kDa
(Figure 1). The relative amount of the ,23 kDa band and the
presence and relative amount of the ,17 kDa band were both
dependent on dose of MMP-9 and the time of incubation. Based
on the dose curve (Figure 1A), 20 mg/mL of SP-D was incubated
with 5 mg/mL of MMP-9, which resulted in the formation of the
23 and 17 kDa fragments after only one minute. After four hours,
all of the SP-D detected had been degraded from its intact, 43 kDa
form into the smaller fragments. In addition, after extensive
cleavage, the 23 kDa band decreased in intensity relative to the
17 kDa band, suggesting that the 23 kDa fragment may be further
digested by MMP-9 (Figure 1B). In order to further analyze the
effect of cleavage on the structure of SP-D, we examined intact
and cleaved SP-D using Native PAGE (Figure 1C). The results
reveal that there is a significant alteration of the multimeric
structure of SP-D after incubation with MMP-9, as changes in the
banding patterns were observed.
SP-D-mediated Bacterial Aggregation is Disrupted by
MMP-9 Cleavage
Incubation with SP-D in vitro results in the agglutination of
a variety of pathogens, including E. coli [30]. In order to examine
the effects of cleavage by MMP-9 on this function, we incubated E.
coli with intact and cleaved SP-D (Figure 2). While incubation with
intact SP-D led to the formation of aggregates of E. coli, incubation
with cleaved SP-D or PBS had no visual effect upon the E. coli
(Figure 2A–C). Incubation with MMP-9 alone also had no visual
effect (not shown). In order to confirm these results in a more
quantitative matter, we monitored the optical density (OD) of
suspensions of E. coli with or without intact and cleaved SP-D, and
only observed a decline in OD with intact SP-D (Figure 2D).
Because multimerization of SP-D is necessary for the formation of
bacterial aggregates after the CRD-mediated interaction of SP-D
with the bacteria, we hypothesize that cleaved SP-D no longer
agglutinates bacteria due to the fact that the multimers are
disrupted.
Loss of the Ability of SP-D to Increase Phagocytosis of E.
coli by Alveolar Macrophages after MMP-9 Cleavage
In addition to agglutination, we also examined the ability of SP-
D to serve as an opsonin for clearance of bound pathogens by host
cells. For our in vitro model, we used a mouse alveolar macrophage
cell line (MH-S). By adding E. coli preincubated with SP-D to these
macrophages, we saw a dose-dependent increase in bacterial
phagocytosis using a gentamicin protection assay (Figure 3A).
After cleavage with MMP-9, the opsonic activity of SP-D was
completely abrogated, and phagocytosis was decreased to levels
comparable with the MMP-9 alone control. In addition to the
gentamicin protection assay, we also used microscopy and flow
cytometry to examine SP-D’s impact on phagocytosis of FITC-
labeled E.coli (Figure 3B, C, and D). Results from these analyses
confirmed those obtained using the gentamicin protection assay,
demonstrating a striking loss of SP-D’s opsonic capacity following
MMP-9 cleavage. Interestingly, the microscopy and flow cytome-
try results suggest that while the numbers of macrophages
containing bacteria are very similar, those that do phagocytose
bacteria contain more in the presence of intact SP-D.
MMP-9–cleaved SP-D Retains CRD-dependent Binding to
LPS
In order to determine if the CRD of the fragmented SP-D
retains its ability to bind to target molecules, we performed an
ELISA using LPS-coated plates. Detection of both intact and
cleaved SP-D was dose-dependent, suggesting that the cleaved SP-
D was able to bind to LPS (Figure 4A). Although intact and
cleaved SP-D were assayed at 1 mg/mL (Fig. 4B), there was
a fivefold lower amount of MMP-9-cleaved SP-D detected;
binding was completely abrogated by the addition of maltose,
suggesting that this binding occurred through the CRD and that
the CRD remained intact after cleavage by MMP-9. The decrease
in the amount of SP-D detected when MMP-9-cleaved SP-D was
assayed may be due to the fact that intact SP-D molecules are
larger, and may bind more of the polyclonal antibody than the
Matrix Metalloprotease 9 Cleaves SP-D
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cleavage fragment containing the CRD; however, it possible that
the cleavage may alter the ability of SP-D to bind LPS or the
stability of this interaction. In contrast to MMP-9-cleaved SP-D,
binding of NE-cleaved SP-D was not detected in this ELISA; this
lack of CRD binding to carbohydrates by NE-cleaved SP-D has
been previously shown by others [43]. This highlights differences
in properties of the cleavage fragments generated by MMP-9 and
NE. We additionally assayed for binding to plates coated with 5%
BSA to control for SP-D binding to the blocking substance;
although both intact and MMP-9-cleaved SP-D were detected,
they were detected at levels significantly lower than that with LPS-
coated plates (p,0.02 for intact and p,0.05 for MMP-9-cleaved,
data not shown). These results indicate that both intact and MMP-
9-cleaved SP-D seem able to bind to E. coli LPS, and this binding
was inhibited by maltose, suggesting it occurs through the CRD.
MMP-9 Cleaves SP-D more Efficiently than Neutrophil
Elastase at Physiological Calcium Concentrations
Cleavage of SP-D by several serine proteases and Pseudomonal
elastase has previously been well-described [43,44,45]. A study by
Cooley et al. showed that of the serine proteases that cleave SP-D
(which consist of neutrophil elastase (NE), cathepsin G, and
proteinase-3), NE is the most potent [46]. However, several studies
have reported that both the cleavage pattern and efficiency of
cleavage by these serine proteases is dependent on the concentra-
tion of calcium [43,46,47]. As we did not expect calcium
concentration to affect cleavage by MMP-9, we compared
MMP-9 cleavage to NE cleavage of SP-D at a variety of calcium
concentrations. As shown in Figure 5, while at low calcium levels
of 0.19 mM, MMP-9 and NE cleave at comparable rates. But at
0.9 mM (the concentration used for all other experiments in this
paper), MMP-9 is much more potent at cleaving SP-D. Cleavage
of SP-D at physiological levels of calcium (2 mM) was similar to
cleavage at 0.9 mM. Therefore, MMP-9 may play a more
important role than serine proteases in regulation of SP-D
function in vivo.
Discussion
The data presented in this manuscript demonstrate the ability of
a single protease, MMP-9, to regulate cleavage of an important
innate immune regulatory molecule of the lung. Dose-dependent
cleavage of SP-D by MMP-9 using levels of protein similar to that
observed in patients with chronic lung disease (Figure 1) suggests in
vivo relevance for this cleavage event. In addition, we demonstrate
that this effect renders alterations in multimeric assembly
(Figure 1C), and cleavage causes SP-D to no longer be able to
agglutinate bacteria (Figure 2). This cleavage further affects SP-D’s
innate immune functions, as bacteria are no longer efficiently
phagocytosed by alveolar macrophages in vitro (Figure 3).
Figure 1. MMP-9 Cleaves SP-D in a Dose- and Time-dependent Manner. (A) Dose and (B) time course digestions of SP-D by MMP-9. For the
dose course (A), the reaction loaded onto lane 2 contained 62 ng/mL MMP-9 and the concentration was raised 3-fold serially to 5 mg/mL MMP-9 at
lane 6. Reactions were incubated for 4 hours. For the time course (B), the length of digestion in minutes is listed above the lane. SP-D concentration
was 20 mg/mL for both experiments, and MMP-9 concentration was 5 mg/mL for the time course. For the Native PAGE (C), lane 1 contains intact SP-D
and lane 2 contains cleaved SP-D. An arrow indicates the band corresponding to MMP-9.
doi:10.1371/journal.pone.0041881.g001
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The finding that MMP-9 is able to cleave SP-D and abrogate
several of its functions in vitro suggests an additional role of MMP-9
over-expression in disease. The interesting links that exist between
these two molecules in human disease and the data presented here
demonstrating their interaction suggests that the effects we saw in
vitro may also occur in human disease. Although we only explored
alterations in the innate immune functions of SP-D, these
alterations could provide a potential mechanism for the increase
in susceptibility to infections in COPD and CF patients. In
addition, recent data has suggested the possibility of whole SP-D
regulating MMP-9 release from alveolar macrophages, suggesting
a potential ‘‘feed-forward’’ loop [48]. Whether or not MMP-9
cleaved SP-D may regulate release from alveolar macrophages is
a question for further investigation.
Although previous studies have shown that several serine
proteases are able to cleave SP-D, their shared cleavage site is in
the CRD, and this cleavage renders SP-D unable to bind targets
through its CRD [43,44]. Contrary to this, cleavage by MMP-9
does not seem to alter CRD function (Figure 4). Therefore, the SP-
D fragments produced by proteolytic cleavage may still have
functions in the host, and these functions might depend on which
protease produced them. Even though MMP-9 cleaved SP-D is
still able to bind to carbohydrates, the overall results strongly
suggest that intact, multimeric SP-D is required for optimal host-
pathogen interactions.
In addition to differences in properties of the fragments
produced, efficiency of cleavage is also different between serine
proteases and MMP-9. While cleavage of SP-D by serine proteases
is dependent on calcium concentration, cleavage by MMP-9 is
unaffected by calcium. At higher concentrations of calcium,
MMP-9 cleaves SP-D much more effectively than NE (Figure 5),
which is the most potent serine protease for SP-D cleavage [46].
As these higher concentrations also represent physiological levels,
MMP-9 may contribute as much to SP-D fragmentation in vivo as
the serine proteases. Interestingly, the CRD of SP-D requires
calcium in order to bind to carbohydrates, so in the low calcium
environment at which serine proteases cleave SP-D most
efficiently, the calcium might not be at optimal levels for CRD
interactions with carbohydrate targets.
It is quite possible that the active cleavage of SP-D will render
a novel mechanism for the pathogenesis in diseases like asthma,
emphysema, and allergies, in which MMP-9 is over-expressed. A
critical component of the impact of these findings in clinical
disorder is to determine the extent of SP-D cleavage and
dysfunction in these conditions; the use of important biomarkers
reflecting this cleavage (such as determination of the amino acid
Figure 2. Cleaved SP-D Fails to Agglutinate E. coli. An equal volume of concentrated bacteria and (A) PBS, (B) 1 mg/mL intact SP-D, or (C) 1 mg/
mL cleaved SP-D were mixed and examined using brightfield microscopy. Original magnification was 1000X. (D) Agglutination was quantitated using
by monitoring the OD700 over time as previously described [50].
doi:10.1371/journal.pone.0041881.g002
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Figure 3. Cleaved SP-D Fails to Increase Phagocytosis by MH-S Cells. Examination and quantitation of phagocytosis of E. coli by MH-S cells
was performed using (A) a gentamicin protection assay and (B and C) flow cytometry. For (A), all conditions are significantly different (p,0.05) from
1 mg/mL intact SP-D. An asterisk (*) denotes p#0.001 when compared to 1 mg/mL intact SP-D. Columns marked with # are significantly different
when compared to 0.5 mg/mL intact SP-D (p,0.05). For (B), intact SP-D causes MH-S cells to have significantly higher mean fluorescence intensity
(MFI) than all other conditions (p#0.001). Cleaved SP-D is significantly different when compared to both MMP-9 and PBS controls (p#0.001). For (C),
flow data was gated on forward and side scatter to select for MH-S cells. For both (A) and (B), error bars represent standard deviation.
doi:10.1371/journal.pone.0041881.g003
Figure 4. Cleaved SP-D Retains its Ability to Bind E. coli LPS. Examination of the ability of SP-D to bind to LPS-coated plates. In (A), the ELISA
was performed using 2-fold serially diluted SP-D samples. In (B), 1 mg/mL intact or cleaved SP-D was analyzed in triplicate with MMP-9 as a control
and NE-cleaved SP-D as a negative control. The average of PBST alone ran in triplicate was subtracted from all values. While intact and MMP-9-cleaved
SP-D in PBST are significantly different from PBST alone (p#0.001 and p,0.05, respectively) and NE-cleaved SP-D (p#0.001 and p,0.05, respectively),
MMP-9 along with intact and cleaved SP-D in PBST with maltose were not significantly different from PBST or PBST with maltose. For (B), error bars
represent standard deviation.
doi:10.1371/journal.pone.0041881.g004
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cleavage fragments from lower airway secretions via mass
spectrometry) may be a mechanism by which to track the loss of
the intact SP-D in disease.
The potential impact of MMP-9 mediated proteolysis of SP-D
may also have broad implications to the cleavage of other collectin
molecules. For example SP-A, another prominent innate immune
molecule, shares significant structural similarity to SP-D and may
also be cleaved and inactivated by MMP-9 [30]. Identifying
similarities and potential differences in the functionality of these
proteins after proteolytic digestion may offer us additional insight
into the roles of these collectins in human lung disorders with
a protease-rich environment.
If MMP-9-mediated proteolytic loss of SP-D does indeed
contribute to disease pathogenesis in clinical disease, there are
potential therapeutic directions by which to target these losses of
SP-D in vivo. One possibility is to neutralize MMP-9 with specific
synthetic inhibitors or the use of endogenous antiproteases;
potential questions certainly exist about tolerability and routes of
delivery of these compounds [49]. If a specific cleavage site could
be determined for MMP-9 cleavage of SP-D, it could be possible
to mutate the cleavage site and create an MMP-9 resistant
recombinant SP-D to be delivered exogenously to patients. Such
a therapeutic might offer a targeted mechanism to improve
bacterial clearance and regulation of lung host defense in the
diseased airway.
Materials and Methods
Bacteria and Macrophages
MH-S cells (ATCC, Manassas, VA, USA) were maintained in
RPMI 1640 (HyClone Laboratories, Logan, Utah, USA) with
10% FBS (Atlanta Biologicals, Lawrenceville, GA, USA) and 1%
Penicilin-Streptomycin Solution (Mediatech, Manassas, VA,
USA).
E. coli DH5a was grown until saturation in LB broth (Becton,
Dickinson, and Company, Sparks, MD, USA) at 37uC with
shaking. Stocks were made by adding glycerol and storing at
280uC.
Cleavage of SP-D by MMP-9
Recombinant human SP-D (R&D Systems, Minneapolis, MN,
USA) was diluted in DPBS with magnesium and calcium
(HyClone, Logan, UT, USA) to a concentration of 20 mg/mL.
Recombinant active human MMP-9 (Calbiochem, San Diego,
CA, USA) was diluted in DPBS with Mg2+ and Ca2+. Cleavage
reactions were carried out at 37uC. For the time course of MMP-9
digestion, reactions were stopped by adding an equal volume of
5XSDS-PAGE Sample Buffer and boiling for 5 min. For
generation of fragments for use in agglutination and phagocytosis
assays, the SP-D concentration was 20 mg/mL and MMP-9 was
5 mg/mL and cleavage was allowed to proceed for 4 hours and
was confirmed by western blot.
Cleavage of SP-D by NE
Cleavage of SP-D by neutrophil elastase was performed as for
MMP-9. Purified NE (Enzo Life Sciences, Farmingdale, NY,
USA) was incubated with 20 mg/mL of recombinant SP-D at
37uC. For generation of fragments for use in the ELISA, 10 mg/
mL NE was incubated with 20 mg/mL SP-D for 1 hour at 37uC.
After cleavage, a portion was analyzed by Western Blot to ensure
complete cleavage of intact SP-D (data not shown).
Western Blots
SP-D digest reactions were analyzed by SDS-PAGE under
reducing conditions using 15% acrylamide gels. After transfer to
a nitrocellulose membrane, blots were blocked with 5% milk, then
incubated with a polyclonal antibody against SP-D diluted 1:2,000
(R&D Systems, Minneapolis, MN, USA) for one hour at 37uC.
Blots were then washed, and a 1:30,000 dilution of anti-goat-HRP
antibody was added (Abcam, Cambridge, UK) for one hour at
37uC. The blots were developed using Supersignal West Femto
(Thermo, Waltham, MA, USA) and imaged using a ChemiDoc
XRS (BioRad, Hercules, CA, USA).
Figure 5. MMP-9 cleaves SP-D more potently than NE at higher calcium concentrations. Comparison of the fragments produced by
cleavage with SP-D and NE. CaCl2 concentrations are listed in mM. For experiments at 0.19 mM CaCl2, incubations were carried out for 10 min at
protease concentrations of 16.95 nM. For experiments at 0.9 and 2 mM CaCl2, incubations were carried out for 4 hours with or without protease at
60.24 nM.
doi:10.1371/journal.pone.0041881.g005
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Native PAGE
SP-D was analyzed by native PAGE using Any KD Mini-
PROTEAN TGX Gels (BioRad, Hercules, CA, USA). 0.5 mg of
either intact or cleaved SP-D was mixed with RunBlue Native
Sample Buffer (Expedeon, San Diego, CA) and electrophoresed in
Tris-Glycine buffer. Protein was visualized using Pierce Silver
Stain Kit (Thermo, Waltham, MA, USA).
Agglutination
Frozen E. coli was thawed, washed, and resuspended in 1/5
original volume of DPBS with Mg2+ and Ca2+. 3.5 mL of
concentrated bacteria was added to 3.5 mL of intact or cleaved
SP-D at 2 mg/mL diluted in DPBS with Mg2+ and Ca2+, MMP-9
diluted in DPBS with Mg2+ and Ca2+ (not shown), or DPBS alone
on a glass slide and coverslip was added. Pictures were taken 5–10
minutes after mixing.
For quantitative analysis, the OD700 of bacterial suspensions
was monitored over time as previously described [50]. Frozen E.
coli was thawed, washed and resuspended in PBS with intact SP-D,
cleaved SP-D, or MMP-9 at an OD700 of ,0.5. Measurements
were taken every 10 minutes.
Phagocytosis Assay
16105 MH-S cells per well were seeded in a 96-well plate and
incubated overnight in a humid incubator at 37uC with 5% CO2.
Bacteria were thawed, washed with HBSS (Mediatech, Manassas,
VA, USA), and diluted to 16107 CFU/mL. SP-D was added to
bacteria at a final concentration of 1 mg/mL and allowed to
incubate at 37uC for 30 min. After washing the MH-S cells three
times in assay buffer (5% FBS in HBSS), 100 mL of bacteria,
bacteria with intact or cleaved SP-D, or bacteria with MMP-9 was
added to wells and incubated at 37uC for 45 min. MH-S cells were
washed three times and 150 mL of 2 mg/mL gentamicin sulfate
was added. The plate was incubated at 37uC for 15 min, washed
three times, then 100 mL of dH20 was added. After 15 minutes,
the lysate was mixed by thorough pipetting, and 10 mL was plated
on LB agar. Agar plates were incubated overnight at 37uC and
CFU counts were performed the following day.
Fluorescence Microscopy and Flow Cytometry
E. coli was FITC labeled by using a modification of a previously
reported protocol [51]. FITC Isomer I (Sigma, St. Louis, MO,
USA) labeling solution was prepared in 0.1 M carbonate/
bicarbonate buffer (pH=9.5) at 0.03%. E. coli frozen stocks were
thawed, washed with HBSS, then resuspended in twice their
original volume of FITC labeling solution and incubated for 20
minutes at room temperature. Bacteria were washed three times,
then resuspended in half their original volume of assay buffer
(HBSS with 5% FBS). FITC-labeled bacteria were used in the
phagocytosis assay described above, except that after washing
unattached bacteria from the macrophages, cells were trypsinized,
washed, and resuspended in a small amount of assay buffer
(,50 mL). For flow cytometry, MH-S cells from three wells that
were given the same treatment were combined. Intact or cleaved
SP-D was used in the assay at a final concentration of 1 mg/mL.
ELISA
Purified E. coli K12 LPS (InvivoGen, San Diego, CA, USA) was
diluted to 1 mg/mL and incubated in a 96-well E.I.A. plate at 4uC
overnight (Costar, Cambridge, MA, USA). The plates were then
washed 3 times using PBS with 0.1% Tween-20 (PBST), and then
blocked with 5% BSA in PBS for 1 hour at 37uC. After washing 3
times, plates were incubated for 1 hour at 37uC with samples
diluted 20-fold in PBST with or without 250 mM maltose. Plates
were washed three times, then incubated sequentially for 2 hours
at 37uC with the same primary and secondary antibodies used in
the western blots described above diluted at 1:200 and 1:20,000,
respectively. Plates were washed between antibody incubations
and afterwards, then developed with TMB substrate (Sigma, St.
Louis, MO, USA) for 1 hour and OD370 was measured on
a Benchmark Plus microplate spectrophotometer (BioRad, Her-
cules, CA, USA).
Statistics
All samples were run in triplicate, and results shown are
representative of at least 3 independent experiments. Descriptive
statistics (mean+ SD) were compared using One-Way ANOVA
with Tukey’s post-hoc test. All statistical tests were performed at
a 5% significance level (i.e., a=0.05) using GraphPad Prism (La
Jolla, CA).
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